Jialiang Li

Jialiang Li

Auto-generated profile, based on publicly available information

Jialiang Li

State Key Laboratory of Frigid Zone Cardiovascular Diseases, Department of Pharmacology, College of Pharmacy, Harbin, Heilongjiang, P.R. China (H.W., Y. Zhuang, Y. Yue, Jiangqi Liu, J.H., Y. Yao, Junwu Liu, Y. Li, Z.Y., Y.W., W.Y., B.M., X.H., Z.T., Y. Yang, Jialiang Li, Y. Zhang, B.Y., Z.P., Y. Lu)

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Phytomedicine
Verified
Journal Article
Closed access
CZChen Zhong
Chen Zhong
SQShuang Qiu
Shuang Qiu
JLJialiang Li
Jialiang Li
JSJingling Shen
Jingling Shen
YZYuangang Zu
Yuangang Zu
GSGuangchao Sui
Guangchao Sui

9 July 2024 in Circulation
Verified
Journal Article
Closed access
DLDesheng Li
Desheng Li
YLYang Liu
Yang Liu
CLChangzhu Li
Changzhu Li
ZZZhiwen Zhou
Zhiwen Zhou
KGKangyi Gao
Kangyi Gao
ZPZhenwei Pan
Zhenwei Pan
BACKGROUND: G protein–coupled receptors play a critical role in atrial fibrillation (AF). Spexin is a novel ligand of galanin receptors (GALRs). In this study, we investigated the regulation of spexin and GALRs on AF and the underlying mechanisms. METHODS: Global spexin knockout (SPX-KO) and cardiomyocyte-specific GALRs knockout (GALR-cKO) mice underwent burst pacing electrical stimulation. Optical mapping was used to determine atrial conduction velocity and action potential duration. Atrial myocyte action potential duration and inward rectifying K + current ( I K1 ) were recorded using whole-cell patch clamps. Isolated cardiomyocytes were stained with Fluo-3/AM dye, and intracellular Ca 2+ handling was examined by CCD camera. A mouse model of AF was established by Ang-II (angiotensin II) infusion. RESULTS: Spexin plasma levels in patients with AF were lower than those in subjects without AF, and knockout of spexin increased AF susceptibility in mice. In the atrium of SPX-KO mice, potassium inwardly rectifying channel subfamily J member 2 ( KCNJ2 ) and sarcolipin ( SLN ) were upregulated; meanwhile, I K1 current was increased and Ca 2+ handling was impaired in isolated atrial myocytes of SPX-KO mice. GALR2-cKO mice, but not GALR1-cKO and GALR3-cKO mice, had a higher incidence of AF, which was associated with higher I K1 current and intracellular Ca 2+ overload. The phosphorylation level of CREB (cyclic AMP responsive element binding protein 1) was upregulated in atrial tissues of SPX-KO and GALR2-cKO mice. Chromatin immunoprecipitation confirmed the recruitment of p-CREB to the proximal promoter regions of KCNJ2 and SLN . Finally, spexin treatment suppressed CREB signaling, decreased I K1 current and decreased intracellular Ca 2+ overload, which thus reduced the inducibility of AF in Ang-II–infused mice. CONCLUSIONS: Spexin reduces atrial fibrillation susceptibility by inhibiting CREB phosphorylation and thus downregulating KCNJ2 and SLN transcription by GALR2 receptor. The spexin/GALR2/CREB signaling pathway represents a novel therapeutic avenue in the development of agents against atrial fibrillation.

Verified
Journal Article
Open access
PDF file
NTNa Tian
Na Tian
JLJialiang Li
Jialiang Li
JSJinming Shi
Jinming Shi
GSGuangchao Sui
Guangchao Sui
Alternative pre-mRNA splicing is a crucial process that allows the generation of diversified RNA and protein products from a multi-exon gene. In tumor cells, this mechanism can facilitate cancer development and progression through both creating oncogenic isoforms and reducing the expression of normal or controllable protein species. We recently demonstrated that an alternative cyclin D-binding myb-like transcription factor 1 (DMTF1) pre-mRNA splicing isoform, DMTF1β, is increasingly expressed in breast cancer and promotes mammary tumorigenesis in a transgenic mouse model. Aberrant pre-mRNA splicing is a typical event occurring for many cancer-related functional proteins. In this review, we introduce general aberrant pre-mRNA splicing in cancers and discuss its therapeutic application using our recent discovery of the oncogenic DMTF1 isoform as an example. We also summarize new insights in designing novel targeting strategies of cancer therapies based on the understanding of deregulated pre-mRNA splicing mechanisms.

1 November 2020 in Journal of Cardiovascular Pharmacology
Verified
Journal Article
Closed access
XZXin Zhao
Xin Zhao
SCShaopeng Cheng
Shaopeng Cheng
SLShouming Li
Shouming Li
JLJialiang Li
Jialiang Li
XBXiao Bai
Xiao Bai
JXJie Xi
Jie Xi
In the present study, the role and molecular mechanism of long noncoding RNA CDKN2B-AS1 in human thoracic aortic dissection (TAD), a highly lethal cardiovascular disease, was investigated. The expression of CDKN2B-AS1 in human TAD and normal aortic tissues of donors were examined by quantitative real-time polymerase chain reaction. RNA pull-down assay and a series of luciferase reporter assays were performed to predict the relationships between CDKN2B-AS1, miR-320d, and STAT3. Cell counting kit 8 (CCK-8), TUNEL, and western blot assays were applied to validate the biological functions of CDKN2B-AS1 in rat aortic vascular smooth muscle cells. Results showed that CDKN2B-AS1 was expressed at a higher level in human TAD than in normal aortic tissues. CDKN2B-AS1 overexpression significantly promoted apoptosis and suppressed the proliferation of vascular smooth muscle cells. CDKN2B-AS1 silence exhibited the opposite effects. Mechanistically, CDKN2B-AS1 was identified as a molecular sponge for miR-320d and positively modulated STAT3 expression via repressing miR-320d. In conclusion, our study revealed that CDKN2B-AS1 was dysregulated and displayed multiple potential functions in human TAD. These findings suggested that CDKN2B-AS1 was a novel potential therapeutic target for human TAD.

10 October 2025 in Circulation Research
Verified
Journal Article
Closed access
HWHao Wu
Hao Wu
YZYuting Zhuang
Yuting Zhuang
YYYing Yue
Ying Yue
JLJiangqi Liu
Jiangqi Liu
JHJin Han
Jin Han
YLYanjie Lu
Yanjie Lu
BACKGROUND: Disturbance in protein synthesis and degradation plays a crucial role in various biological and pathological processes. E3 ubiquitin ligase substrate–binding adaptor SPOP (speckle-type POZ [poxvirus and zinc finger] protein) is substantially involved in cancer progression. The study aims to investigate the biological function of SPOP in cardiac hypertrophy and heart failure. METHODS: We generated cardiac-specific transgenic and knockout mice to evaluate the functional role of SPOP in transverse aortic constriction–induced cardiac hypertrophy and heart failure. RNA-sequencing, proteomics, and protein mass spectrometry analysis, and multiple molecular biological methodologies were employed to investigate its function and mechanisms in cardiac hypertrophic mice. RESULTS: SPOP was significantly upregulated in human heart failure, hypertrophic mouse hearts, and Ang II (angiotensin II)–treated neonatal mouse ventricular cardiomyocytes. SPOP induced the expression of hypertrophic markers ANP (atrial natriuretic peptide), BNP (B-type natriuretic peptide), and β-MHC (β-myosin heavy chain), increased cardiomyocyte size, whereas SPOP deficiency exhibited the opposite effects in hypertrophic neonatal mouse ventricular cardiomyocytes. Furthermore, cardiac-specific overexpression of SPOP led to cardiac hypertrophy and heart failure in mice. In contrast, cardiac-specific knockout of SPOP markedly attenuated transverse aortic constriction–induced cardiac hypertrophy and improved heart failure. In parallel, SPOP presented prohypertrophic effects, and SPOP loss-of-function substantially rescued Ang II–induced hypertrophic phenotype in neonatal mouse ventricular cardiomyocytes. Mechanistically, SPOP is transcriptionally activated by p300 under cardiac hypertrophy, subsequently interacting with and promoting ubiquitination-mediated degradation of TFEB (transcription factor EB) independently of its phosphorylation status, a key regulator for transcription of lysosomal biogenesis and autophagy-related genes, leading to blockage of autophagy and mitophagy, which eventually causes cardiac hypertrophy and heart failure. Overexpression of TFEB rescued SPOP-induced these alterations. Noticeably, a specific inhibitor of SPOP was able to prevent the development of cardiac hypertrophy and heart failure. CONCLUSIONS: SPOP is a detrimental factor in pathological cardiac hypertrophy via promoting ubiquitination-induced degradation of TFEB, a critical regulator of the autophagy-lysosomal pathway. Targeting SPOP represents a promising therapeutic strategy for hypertrophy-related heart failure.

22 July 2021 in RNA Biology
Verified
Journal Article
Closed access
JLJialiang Li
Jialiang Li
GLGuangyue Li
Guangyue Li
YQYige Qi
Yige Qi
YLYao Lu
Yao Lu
HWHao Wang
Hao Wang
GSGuangchao Sui
Guangchao Sui
Among the three DMTF1 splicing isoforms, DMTF1 alpha acts as a tumour suppressor through promoting p14ARF expression, while DMTF1 beta exhibits an oncogenic role likely through antagonizing DMTF1 alpha. However, the molecular mechanism underlying alternative splicing of DMTF1 pre-mRNA has not been delineated. In the current study, we discovered SRSF5 as a regulatory protein binding to a region located between DMTF1 beta and alpha acceptor splice sites to promote DMTF1 beta and gamma splicing. We demonstrated that SRSF5 expression positively correlated with DMTF1 beta/alpha ratio in breast cancer samples, and ectopically expressed SRSF5 promoted the splicing of DMTF1 beta and gamma, but not DMTF1 alpha, when testing endogenous DMTF1 pre-mRNA and a reporter construct. Upon SRSF5 knockdown, we observed significantly decreased DMTF1 beta and gamma ratios of endogenous transcripts. An RNA sequence just upstream of the alpha acceptor site contains two adjacent SRSF5 binding elements, one of which overlaps with an SF1 binding site. Our mechanistic studies revealed that SRSF5 binding to both elements in this region could consign SF1 to its distal-binding sites close to the beta and gamma acceptor sites, favouring splicing of their isoforms. Overall, our study revealed SRSF5 as a key regulator to promote DMTF1 beta and gamma splicing, and consequently reduce DMTF1 alpha splicing.